Sartorius Stedim Biotech

Sartorius Stedim Biotech's mission is to 'simplify progress' by providing the essential technologies and services that translate scientific discoveries into effective therapies faster and more reliably. The company has achieved a leading global position as a supplier of single-use bioprocessing solutions, serving all major pharmaceutical and biotech companies and generating approximately €3.5 billion in sales revenue in 2025. Its strategy centers on expanding its integrated platform of hardware, consumables, and digital data analytics solutions to capitalize on the rapid growth in biologics, cell and gene therapies, and process intensification.

Integrated single-use bioprocessing platform encompassing hardware (bioreactors, fluid management), consumables, and digital data analytics software (BioPAT®) designed to simplify, accelerate, and intensify the development and production of biologics and advanced therapies.

Sartorius competes in a consolidated landscape against full-line giants Danaher (Cytiva) and Thermo Fisher, as well as Merck KGaA. Its advantage lies in deep bioprocessing specialization and an integrated portfolio, but it faces constant pressure from competitors with greater scale and R&D budgets.